What are minimal important changes for asthma measures in a clinical trial?

In this study, the perceptions of asthmatics to change in their disease was associated with observed changes in clinical asthma measures, in order to identify the threshold where changes in clinical asthma measures are perceivable by patients. The study included 281 asthmatic patients, aged 18-63 yrs, in a randomized, placebo-controlled clinical trial of a leukotriene antagonist. Changes were related in: 1) asthma symptom scores; 2) inhaled beta-agonist use; 3) forced expiratory volume in one second (FEV1); and 4) peak expiratory flow (PEF) to a global question that queried overall change in asthma since starting the study drug. Additional analyses examined differences in the group reporting minimal improvement by treatment (active treatment versus placebo), sex and age groups. The average minimal patient perceivable improvement for each measure was: 1) -0.31 points for the symptom score on a scale of 0-6; 2) -0.81 puffs x day(-1) for inhaled beta-agonist use; 3) 0.23 L for FEV1; and 4) 18.79 L x min(-1) for PEF. In general placebo-treated patients and older patients, who reported minimal improvement, experienced less mean improvement from baseline than active-treated patients and younger patients, who reported minimal improvement. Determining the minimal patient perceivable improvement value for a measure may be helpful to interpret changes. However, interpretation should be carried out cautiously when reporting a single value as a clinically important change.

This article has been cited by other articles:

				G. J. Rodrigo Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest, November 1, 2006; 130(5): 1301 - 1311. [Abstract] [Full Text] [PDF]

				S. M Haley and M. A Fragala-Pinkham Interpreting Change Scores of Tests and Measures Used in Physical Therapy Physical Therapy, May 1, 2006; 86(5): 735 - 743. [Abstract] [Full Text] [PDF]

				G J Rodrigo and J A Castro-Rodriguez Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis Thorax, September 1, 2005; 60(9): 740 - 746. [Abstract] [Full Text] [PDF]

				B. Barrett, D. Brown, M. Mundt, and R. Brown Sufficiently Important Difference: Expanding the Framework of Clinical Significance Med Decis Making, May 1, 2005; 25(3): 250 - 261. [Abstract] [PDF]

				J. F. Donohue and J. A. Ohar Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 152 - 160. [Abstract] [Full Text] [PDF]

				D. Wensley and M. Silverman Peak Flow Monitoring for Guided Self-management in Childhood Asthma: A Randomized Controlled Trial Am. J. Respir. Crit. Care Med., September 15, 2004; 170(6): 606 - 612. [Abstract] [Full Text] [PDF]

				M Masoli, M Weatherall, S Holt, and R Beasley Clinical dose-response relationship of fluticasone propionate in adults with asthma Thorax, January 1, 2004; 59(1): 16 - 20. [Abstract] [Full Text] [PDF]

				G. J. Rodrigo and C. Rodrigo The Role of Anticholinergics in Acute Asthma Treatment* : An Evidence-Based Evaluation Chest, June 1, 2002; 121(6): 1977 - 1987. [Abstract] [Full Text] [PDF]

				E.D. Bateman, J. Bousquet, and G.L. Braunstein Is overall asthma control being achieved? A hypothesis-generating study Eur. Respir. J., April 1, 2001; 17(4): 589 - 595. [Abstract] [Full Text] [PDF]

				B. Stenius-Aarniala, T. Poussa, J. Kvarnström, E.-L. Grönlund, M. Ylikahri, and P. Mustajoki Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study BMJ, March 25, 2000; 320(7238): 827 - 832. [Abstract] [Full Text]